title: Effects of chronic methylphenidate in adolescence on later methylphenidate self-administration in rhesus monkeys.
abstract: Many children diagnosed with attention deficit hyperactivity disorder are treated with methylphenidate (MPH), despite limited information on later vulnerability to drug abuse. A previous study in adolescent monkeys treated with MPH for 1 year did not indicate differences in acquisition to cocaine reinforcement compared with controls. The present study extended this characterization to include MPH self-administration. Adolescent male rhesus monkeys treated previously with a sustained-release formulation of MPH (beginning at ∼30 months old) and control monkeys (n=8/group) were used. All had previous experience of self-administering cocaine under a fixed-ratio 30 schedule of reinforcement. Responding was maintained by food (1.0-g banana-flavored pellets) and MPH (saline, 0.001-0.1 mg/kg/injection) was substituted for food for at least five consecutive sessions. MPH functioned as a reinforcer in all monkeys; there were no differences between groups in MPH self-administration. These findings extend earlier research with cocaine reinforcement showing that MPH treatment in adolescent monkeys does not increase future reinforcing effects of stimulant drugs.
authors.affiliation: Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1083, USA.
authors.forename: Susan E
authors.initials: SE
authors.lastname: Martelle
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Porrino
authors.forename: Michael A
authors.initials: MA
authors.lastname: Nader
mesh_terms: D000818:Animals; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D003216:Conditioning, Operant / Q000187:drug effects*; D004334:Drug Administration Schedule; D008253:Macaca mulatta; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage*; D012646:Self Administration; D013997:Time Factors
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate
references.citation: J Pharmacol Exp Ther. 1975 May;193(2):676-88
references.pmid: 1142112
references.citation: Behav Brain Res. 2002 Mar 10;130(1-2):65-71
references.pmid: 11864719
references.citation: Neurosci Biobehav Rev. 2003 Nov;27(7):615-21
references.pmid: 14624806
references.citation: J Pharmacol Exp Ther. 1989 Oct;251(1):150-5
references.pmid: 2529365
references.citation: Behav Pharmacol. 2012 Oct;23(7):650-7
references.pmid: 22914073
references.citation: J Am Acad Child Adolesc Psychiatry. 2000 Feb;39(2):182-93
references.pmid: 10673829
references.citation: Neuropsychopharmacology. 2011 Jan;36(1):207-26
references.pmid: 20881946
references.citation: J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):980-9
references.pmid: 20855043
references.citation: Pharmacol Biochem Behav. 2001 Mar;68(3):611-27
references.pmid: 11325419
references.citation: Pediatrics. 2006 Dec;118(6):2472-80
references.pmid: 17142533
references.citation: J Pharmacol Exp Ther. 2003 Oct;307(1):356-66
references.pmid: 12954808
references.citation: Neuropsychopharmacology. 2012 Nov;37(12):2555-65
references.pmid: 22805600
references.citation: Psychopharmacology (Berl). 2011 Jan;213(1):43-52
references.pmid: 20848087
references.citation: Vital Health Stat 10. 2008 Jul;(237):1-14
references.pmid: 18998276
references.citation: BMC Med. 2011 Jun 10;9:72
references.pmid: 21658285
references.citation: Neuropsychopharmacology. 2012 Nov;37(12):2566-79
references.pmid: 22805599
references.citation: Arch Gen Psychiatry. 1995 Jun;52(6):456-63
references.pmid: 7771915